KCTD7-related progressive myoclonus epilepsy

Area of Science:

• Genetics
• Neurology
• Epilepsy

Background:

• Progressive myoclonic epilepsy (PME) is a group of rare neurological disorders.
• Mutations in the KCTD7 gene have been identified as a cause of a specific PME subtype.
• This condition presents in infancy with distinct neurological and developmental features.

Purpose of the Study:

• To describe the clinical spectrum and genetic basis of KCTD7-associated epilepsy.
• To analyze the genotype-phenotype correlations in affected individuals.
• To understand the long-term prognosis and potential for stabilization.

Main Methods:

• Clinical data collection from 19 patients across 12 families.
• Genetic analysis focusing on homozygous mutations in the KCTD7 gene.
• Electroencephalogram (EEG) and neurological assessments.

Main Results:

• Homozygous mutations in KCTD7 gene identified in all patients.
• Onset in infancy with severe epileptic disorder, cognitive regression, and ataxia.
• Myoclonic seizures and abundant epileptiform discharges on EEG are prominent.
• Action-aggravated myoclonus observed in over half of cases.
• Disease course shows stabilization after initial years, with potential for long survival and independent ambulation.

Conclusions:

• KCTD7 mutations cause a distinct infantile-onset epilepsy syndrome with variable severity.
• The epileptic disorder may significantly contribute to neurological regression.
• Long-term stabilization and survival are possible, suggesting a potential therapeutic window.